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Background: Tks5/FISH is a scaffold protein comprising of five SH3 domains and one PX domain. Tks5 is a
substrate of the tyrosine kinase Src and is required for the organization of podosomes/invadopodia implicated in
invasion of tumor cells. Recent data have suggested that a close homologue of Tks5, Tks4, is implicated in the EGF
signaling.
Results: Here, we report that Tks5 is a component of the EGF signaling pathway. In EGF-treated cells, Tks5 is
tyrosine phosphorylated within minutes and the level of phosphorylation is sustained for at least 2 hours. Using
specific kinase inhibitors, we demonstrate that tyrosine phosphorylation of Tks5 is catalyzed by Src tyrosine kinase.
We show that treatment of cells with EGF results in plasma membrane translocation of Tks5. In addition, treatment
of cells with LY294002, an inhibitor of PI 3-kinase, or mutation of the PX domain reduces tyrosine phosphorylation
and membrane translocation of Tks5.
Conclusions: Our results identify Tks5 as a novel component of the EGF signaling pathway.
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Epidermal growth factor receptor (EGFR) is involved in
diverse cellular processes, including proliferation and
motility; however, it is also implicated in the develop-
ment of various human cancers [1]. A number of signal-
ing pathways have been identified through which EGFR
may regulate rearrangement of actin cytoskeleton, such
as activation of phospholipase Cγ1 [2] and Rho GTPases
[3,4]. It has been well established that EGF may also
signal to actin cytoskeleton via Src tyrosine kinase [5-7].
Recently, the Frank-ter Haar syndrome protein Tks4/
HOFI/SH3PXD2B/fad49 (tyrosine kinase substrate with
four SH3 domains / homolog of FISH / SH3 and PX
domain-containing protein 2B / factor for adipocyte dif-
ferentiation 49, hereafter termed Tks4) has emerged as a
candidate scaffold molecule that has the capability to* Correspondence: buday.laszlo@ttk.mta.hu
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reproduction in any medium, provided the orregulate actin cytoskeleton via Src and EGFR [8,9]. In
addition, Tks4 was shown to play an important role in
the formation of functional podosomes [10], production
of reactive oxygen species (ROS) by tumor cells [11-13],
and in the differentiation of white adipose tissue [14].
A close homolog of Tks4 is Tks5/FISH that was first
identified as a Src substrate containing one PX and five
SH3 domains [15]. Tks5 was shown to be localized at
the podosomes of Src-transformed cells and associated
with some members of the ADAM metalloprotease
family [16]. Later, Tks5 was found to be expressed in
podosomes in invasive cancer cells. In addition, Tks5
expression was required for protease-driven matrigel
invasion in human cancer cells [17]. In this process Nck
adaptor proteins, Nck1 and Nck2, seem to link Tks5 to
invadopodia actin regulation and extracellular matrix
degradation [18]. Very recently, Tks5 has been shown
to be required for migration of neural crest cell during
development of zebrafish embryos [19].
In the present study we have investigated the involve-
ment of Tks5 in the EGF signaling pathway. Here we
show that upon EGF stimulation of A431 or COS7 cellsLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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inhibitors, we demonstrate that EGF-dependent tyro-
sine phosphorylation of Tks5 is catalyzed by Src tyro-
sine kinase. Interestingly, challenge of cells with EGF
results in plasma membrane translocation of the scaf-
fold protein. In addition, treatment of cells with
LY294002 or BKM120, inhibitors of PI 3-kinase, or
mutation of the PX domain reduces tyrosine phosphor-
ylation and membrane translocation of Tks5. Our
results suggest that Tks5 as a novel component of the
EGF signaling pathway.
Results
Tks5 is tyrosine phosphorylated in response to EGF
Recently, we have shown that Tks4 is implicated in EGF-
dependent regulation of actin cytoskeleton [8,9], therefore,
we have asked if Tks5, the homolog of Tks4, is also
involved directly in the EGF signaling pathway. Serum-
starved A431 cells were stimulated with EGF for 10 min or
left untreated and then endogenous Tks5 was immuno-
precipitated with a polyclonal anti-Tks5 antibody. As seen
in Figure 1A, Tks5 is subject of tyrosine phosphorylation
in response to EGF stimulation. To confirm the involve-
ment of Tks5 in the EGF signaling pathway in another cell
system, V5 epitope-tagged Tks5 was transiently expressed
in COS7 cells, then after EGF stimulation Tks5 was
immunoprecipitated with an anti-V5 antibody. Figure 1B
demonstrates that in this system V5-Tks5 is also tyrosine
phosphorylated upon EGF treatment. These results suggest
that Tks5 is involved in the EGF signaling pathway.
In 1998, Lock et al. investigated if growth factor
stimulation resulted in tyrosine phsophorylation of
Tks5/FISH [15]. Testing a variety of stimuli they foundFigure 1 Tks5 is tyrosine phosphorylated upon EGF treatment of cells
for 10 min, and then endogenous Tks5 was immunoprecipitated (IP) with a
nitrocellulose, samples were analysed by anti-phosphotyrosine and anti-Tks
expressed in COS7 cells and then serum-starved cells were stimulated with
immunoprecipitated with anti-V5 antibody and the immunoprecipitates we
(C) V5 epitope-tagged Tks5 was transiently expressed in COS7 cells and the
indicated. Cell lysates were immunoprecipitated with anti-V5 antibody and
phosphotyrosine and anti-V5 antibodies. These results are representative ofthat treatment of Rat1 fibroblasts with PDGF, LPA,
and bradykinin increased the tyrosine phosphorylation
of Tks5/FISH. Interestingly, the kinetics of phosphoryl-
ation was quite slow in response to PDGF, reaching
maximal intensity 2 h after stimulation [15]. Therefore,
we measured the time course of tyrosine phosphoryl-
ation of Tks5 in response to EGF. V5-Tks5 was transi-
ently expressed in COS7 cells and they were stimulated
with EGF for the indicated time periods. Figure 1C
demonstrates that the level of phosphorylation reaches
its maximum after 5 minutes and this intensity is
almost unchanged over the 2 h time period.
Phosphorylation of Tks5 requires Src kinase
Considering that both Tks4 and its close kin Tks5 are
prominent substrates of the Src tyrosine kinase impli-
cated in podosome formation [10,15-17], we supposed
that tyrosine kinase Src may be responsible for Tks5
phosphorylation upon EGF stimulation. To challenge
our hypothesis, COS7 cells expressing V5-Tks5 were
pre-treated with three specific inhibitors of Src, PP1,
PP2, and Src kinase inhibitor I, respectively, and
following EGF treatment V5-Tks5 was immunopre-
cipitated and subjected to anti-phosphotyrosine im-
munoblot. All of the inhibitors markedly decreased
tyrosine phosphorylation of Tks5, reflecting the Src
kinase is responsible for Tks5 phosphorylation upon
EGF stimulation (Figure 2A). To prove that PP1 can
also block the tyrosine phosphorylation of the endo-
genous Tks5, Tks5 was immunoprecipitated from ly-
sates of EGF-treated A431 cells. As seen in Figure 2B,
PP1 was capable of inhibiting the EGF-induced tyrosine
phosphorylation of Tks5.. (A) Serum-starved A431 cells were stimulated with EGF (50 ng/ml)
polyclonal anti-Tks5 antibody. After SDS-PAGE and transfer to
5 antibodies. (B) Wild type, V5 epitope-tagged Tks5 was transiently
EGF (50 ng/ml) for 10 min or left untreated. Cell lysates were
re immunoblotted with anti-phosphotyrosine and anti-V5 antibodies.
n serum-starved cells were stimulated with EGF (50 ng/ml) as
the immunoprecipitates were immunoblotted with anti-
three experiments.
Figure 2 Phosphorylation of Tks5 upon EGF stimulation requires Src. (A) COS7 cells were transiently transfected with V5-Tks5 construct and
after overnight serum-starvation cells were stimulated with EGF or left untreated. Prior to stimulation, the cells were pretreated with the Src
kinase inhibitors as indicated. Tks5 was then immunoprecipitated with anti-V5 antibody and subjected to anti-phosphotyrosine and anti-V5
immunoblots. (B) Serum-starved A431 cells were stimulated with EGF (50 ng/ml) for 10 min. Prior to stimulation, the cells were pretreated with
the Src kinase inhibitor PP1 and the PI 3-kinase inhibitor LY294002. Endogenous Tks5 was immunoprecipitated (IP) with a polyclonal anti-Tks5
antibody. After SDS-PAGE and transfer to nitrocellulose, samples were analysed by anti-phosphotyrosine and anti-Tks5 antibodies. Cell lysates
were also probed with anti-pAKT (Ser473) or anti-Akt antibodies. These results are typical of at least three experiments.
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of Tks5
The family of Tks proteins possesses a Phox homology
(PX) domain which can bind specific membrane lipids,
such as PtdIns(3)P and PtdIns(3,4), and is implicated in
the appropriate cellular localization of Tks4 and Tks5
[9,10,15-17]. Therefore, we asked first if activation of
PI 3-kinase producing PtdIns(3)P and PtdIns(3,4) is
required for Tks5 phosphorylation. V5 epitope-tagged,
wild type Tks5 was transiently expressed in COS7 cells,
cells were pretreated with specific PI 3-kinase inhibitors,
LY294002 or BKM120, respectively, and then they were
stimulated with EGF or left untreated. As shown in
Figure 3A, EGF-dependent phosphorylation of Tks5
could be inhibited by the addition of both specific inhib-
itors. To verify that the specific PI 3-kinase inhibitors
really inhibited the enzyme, anti-phospho-Akt immuno-
blot was preformed from cell lysates. Figure 2B and
Figure 3A demonstrate that PI 3-kinase inhibitors
blocked effectively the tyrosine phosphorylation of either
the endogenous or the V5 epitope-tagged Tks5.
To confirm that the intact PX domain is instrumental
for the adequate tyrosine phosphorylation, a point muta-
tion was introduced into the PX domain of Tks5 chan-
ging its conserved arginine 42 to alanine, as described
earlier [16,20]. Similar mutation was identified in the
structure of Tks4 PX domain leading to the change ofthe highly conserved arginine 43 to triptophan which
resulted in the development of Frank-ter Haar syndrome
[21]. Latter mutation was predicted to abolish binding to
phosphoinositides [21]. Figure 3B shows that the muta-
tion R42A in the PX domain considerably reduced the
tyrosine phosphorylation of Tks5. Collectively, these
findings suggest that the lipid products of PI 3-kinase
and their binding target, the PX domain, are instrumen-
tal for the proper tyrosine phosphorylation of Tks5.
EGF induces translocation of Tks5 to the
plasma membrane
Since the lipid products of PI 3-kinase may recruit Tks5
from the cytosol to the plasma membrane, therefore, we
investigated the intracellular rearrangement of Tks5
upon EGF stimulation by confocal microscopy. To this
end, V5 epitope-tagged Tks5 was expressed in COS7
cells. In quiescent cells, Tks5 showed a uniform cyto-
plasmic distribution, with membrane localization in only
a low proportion of cells (approx. 6%, Figure 4B). In
response to EGF, Tks5 was seen to be translocated
to membrane ruffles in approximately 35% of cells
(Figure 4). However, when cells were pre-treated with
LY294002, membrane translocation of Tks5 was somewhat
inhibited, suggested that the lipid products generated by PI
3-kinase upon EGF treatment mediate, at least partially,
Tks5 recruitment to the plasma membrane (Figure 4B).
Figure 3 PI 3-kinase and intact PX domain are required for tyrosine phosphorylation of Tks5. (A) COS7 cells were transiently transfected
with V5-Tks5 and after serum-starvation cells were stimulated with EGF or left untreated. Prior to stimulation the cells were treated with the PI
3-kinase inhibitors LY294002 and BKM120, respectively. Tks5 proteins were immunoprecipitated with anti-V5 antibody and subjected to
anti-phosphotyrosine and anti-V5 immunoblots. Cell lysates were also probed with anti-pAKT (Ser473) or anti-Akt antibodies. (B) COS7 cells were
transiently transfected with the V5-Tks5R42A construct and challenged with EGF. Cell lysates were then subjected to immunoprecipitation with
anti-V5 antibody. Bound proteins were separated by SDS-PAGE, transferred to nitrocellulose, and probed with anti-phosphotyrosine and anti-V5
antibodies. These results are typical of at least three experiments.
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domain was also tested. While in serum-starved cells
membrane localization of the mutant Tks5 was not signifi-
cantly different from that of the wild type protein, EGF
treatment did not induce significant membrane transloca-
tion of Tks5 R42A. It is worth to note that although we did
not see any difference in the expression levels of wild
type and PX domain mutant proteins when they were
immunoprecipitated from lysates of COS7 cells, pictures of
confocal microscopy suggest that in some of the cells ex-
pressing the mutant protein, Tks5 R42A is concentrated
next to the nuclei in so called aggresomes (data not
shown), reflecting that, similar to the PX domain mutant
Tks4, a fraction of mutant Tks5 is likely misfolded [9].
Taken together, these results suggest that EGF regulates
Tks5 membrane translocation and this process requires an
intact PX domain and the activity of PI 3-kinase.
Discussion
Recently, we have shown in two studies that Tks4, a kin
of Tks5, plays an important role in EGF signaling, regu-
lating the rearrangement of actin cytoskeleton [8,9].
Therefore, in this paper we have investigated if Tks5
could also contribute to EGF signaling. Upon short-termEGF treatment, both endogenous and overexpressed
Tks5 were seen to be tyrosine phosphorylated (Figure 1).
Although Tks5 was reported earlier to be phosphory-
lated in Rat1 fibroblasts upon PDGF stimulation, the
kinetics of phosphorylation was quite slow, reaching
maximal intensity 2 h after stimulation [15]. Therefore,
we evaluated V5-Tks5 tyrosine phosphorylation after
different intervals of EGF stimulation in COS7 cells. As
shown in Figure 1C, level of tyrosine phosphorylation of
Tks5 reaches its maximum after 5 minutes and its inten-
sity is almost unchanged over the 2 h time period. This
later time course of Tks5 phosphorylation resembles
better other proteins seen to be phosphorylated in
response to growth factors [22-24].
It has been well established that both Tks4 and Tks5
are prominent substrates of the Src tyrosine kinase
[8-10,15-17]. Therefore, it is not surprising that Src tyro-
sine kinase is responsible for Tks5 phosphorylation upon
EGF stimulation (Figure 2). However, the mechanism by
which Src phosphorylates the scaffold proteins may dif-
fer. In the case of Tks4, stable association of Tks4 with
Src was detected in cells over-expressing the kinase [8]. In
COS7 cells, upon EGF treatment, inducible interaction
was revealed between Tks4 and Src [9]. Conversely, we
Figure 4 (See legend on next page.)
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Figure 4 EGF induces membrane translocation of Tks5 in response to EGF treatment. (A) COS7 cells were transiently transfected with V5-
Tks5 and after serum-starvation cells were stimulated with EGF (G, H, I) or left untreated (A, B, C). V5-Tks5R42A construct was also transiently
expressed in the cells and after serum-starvation they were treated with EGF (J, K, L) or left untreated (D, E, F). Cells were then fixed and
processed for immunofluorescence. Subcellular localization of Tks5 was detected using V5-specific monoclonal antibody (B, E, H, and K). To
visualize membrane ruffles, cells were also stained with TRITC-phalloidin (A, D, G, and J). Arrows indicate Tks5 present at the plasma membrane.
The scale bar represents 20 μm. (B) Quantitative analysis of Tks5 translocation upon EGF treatment. COS7 cells were transiently transfected with
V5-Tks5 and V5-Tks5R42A constructs and after serum-starvation cells were stimulated with EGF or left untreated. Prior to stimulation a part of the
cells expressing V5-Tks5 were treated with the PI 3-kinase inhibitor LY294002 as indicated. The percentage of cells translocated to the plasma
membrane under different conditions was quantified by an observer who was blinded to cell treatment status (n = 100 cells for each group per
experiment). Error bars represent the Standard Error of the Mean, SEM. ***: p < 0.001, **: p < 0.005
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Src and Tks5 in COS7 cells challenged with EGF (data not
shown). These findings suggest that the interaction of
Tks4 with Src is likely to be more stable than that of Tks5.
Very recently, we have shown that Tks4 forms a com-
plex with the EGF receptor upon EGF stimulation of
cells [9]. Since the interaction of Src kinase with the
EGF receptor has been well established, we propose that
Src serves as an adaptor molecule which bridges
between the EGFR and Tks4. Indeed, we were able to
detect an inducible interaction between Tks4 and Src. In
addition, expression of SH2 or SH3-deleted mutants of
Src in the cells prevented the interaction of Tks4 with
EGFR [9]. In contrast, we were not capable of detecting
interaction of Tks5 with either Src or the EGF receptor.
This finding suggests that although the general structure
of Tks4 and Tks5 is very similar their function and
regulation are only partially overlapping.
Protein-lipid interaction is a well-underlined mechan-
ism by which eukaryotic cells regulate membrane re-
cruitment [25]. The family of Tks proteins possesses a
Phox homology (PX) domain which can bind specific
membrane lipids and is implicated in the appropriate
cellular localization of Tks4 and Tks5. The PX domain
of both Tks4 and Tks5 shows a very similar binding
affinity, the preferred lipids are the lipid products of the
PI 3-kinase [8-10,16]. Here we show that the PX domain
is instrumental for Tks5 to participate properly in the
EGF signaling pathway. Point mutation was introduced
into the PX domain of Tks5 changing the conserved
arginine 42 to alanine, as described earlier [16]. Intri-
guingly, this mutant was not able to be phosphorylated on
tyrosine residues upon EGF treatment (Figure 3B). More-
over, when cells were pretreated with specific inhibitors of
PI 3-kinase, EGF-dependent tyrosine phosphorylation of
Tks5 was also markedly inhibited (Figure 2B and 3A).
When subcellular localization of Tks5 was analyzed by
confocal microscopy in EGF treated cells, a significant
fraction of Tks5 was seen to be translocated from the
cytoplasm to the plasma membrane (Figure 4). This effect
was partially prevented by addition of PI 3-kinase in-
hibitor LY294002. Intriguingly, when an inactivating
point mutation (R42A) was introduced into in the PXdomain, Tks5 lost its capability to translocate to the
plasma membrane upon EGF challenge (Figure 4).
Taken together, we propose that Tks5 is recruited to
the plasma membrane via its PX domain in response to
EGF treatment. This is reflected in the fact that muta-
tion of one of the conserved arginins in the PX domain
known to be essential for lipid binding strongly inhibited
the membrane translocation of Tks5. In addition, we
found that this Tks5 mutant did not become phosphory-
lated in EGF-treated cells, suggesting that it could not
get in proximity with the membrane-associated Src
kinase. Furthermore, membrane translocation of Tks5
requires the activity of PI 3-kinase which is responsible
for generating inositol-phospholipids to recruit the PX
domain. We have to note that unlike Tks5 Tks4 seems
to be recruited to the plasma membrane through at least
two independent sites [9]. These are the PX domain
which binds the lipid products of PI 3-kinase, and the
tyrosine kinase Src which can form an inducible com-
plex with Tks4 at the plasma membrane linking Tks4 to
the activated EGF receptor. It is not unique that a regula-
tory protein requires two independent sites for membrane
translocation. For example, the guanine nucleotide ex-
change factor Sos is recruited to the membrane through
interactions with the SH3 domains of adaptor protein
Grb2, while its PH domain binds certain phospholipids,
such as lipid products of PI 3-kinase or phosphatidic acid
[26]. Further experiments will be necessary in the future
to reveal why the regulation of Tks5 differs significantly
from that of Tks4.
Conclusion
This study has shown that the scaffold protein Tks5 is a
player in the EGF signaling pathway.
It seems that upon EGF treatment, Tks5 is tyrosine
phosphorylated within minutes and the level of phosphor-
ylation is sustained for at least 2 hours. We have proved
that the tyrosine kinase Src is responsible for the phos-
phorylation. In addition, the lipid products of PI 3-kinase
and the PX domain of Tks5 are instrumental for the EGF-
dependent membrane translocation of the scaffold protein.
Further experiments will be required to establish the
physiological role of Tks5 in the EGF signaling.
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Antibodies, constructs and reagents
Antibody against phosphotyrosine residues (clone 4G
10, 05–321) was obtained from Millipore (Billerica,
MA). Antibody against the V5 epitope (R96025) was
ordered from Invitrogen (Carlsbad, CA). Antibodies
against pAKT1/2/3 (sc-33437), AKT (sc-5298), and
Tks5 (Fish, M-300, sc-30122) were purchased from
Santa Cruz Biotechnology, Inc. (Santa Cruz, CA). Anti-
body against Src (2109) was obtained from Cell Signal-
ing Technology (Beverly, MA). Alexa Fluor 488 rabbit
anti-mouse (A11059) antibody was purchased from
Invitrogen (Carlsbad, CA). V5-Tks5R42A mutant was
generated using the QuickChange Site-Directed Muta-
genesis Kit (Stratagene, La Jolla, CA). Stock solutions
of epidermal growth factor (EGF, Sigma-Aldrich), PP1
(Biomol, Hamburg, Germany), PP2, Src kinase inhibitor I,
BKM120 (Santa Cruz Biotechnology, Inc.) and LY294002
(Merck, Darmstadt, Germany) were prepared according to
the manufacturer’s instructions.
Cell lines, transfection and stimulation
A431 and COS7 cells were purchased from American Type
Culture Collection and maintained in Dulbecco’s modified
Eagle’s medium (DMEM, Invitrogen) supplemented with
10% Foetal Bovine Serum, penicillin (100 units/ml),
streptomycin (100 μg/ml) and L-Glutamine (2 mM). COS7
cells were transiently transfected with Lipofectamine
(Invitrogen) according to the manufacturer’s instructions.
For stimulation, cells were serum-starved overnight and
stimulated with EGF at 50 ng/ml for 10 min. Alternatively,
cells were pre-treated with the PI 3-kinase inhibitors
(LY294002 at 20 μM and BKM120 at 5 μM) or the Src
inhibitors (PP1 at 10 μM, PP2 at 10 μM, and Src kinase
2inhibitor I at 5 μM) for 60 min and then stimulated with
EGF as above.
Confocal microscopy
COS7 cells plated on glass cover slips were transiently
transfected with V5-Tks5 or V5-Tks5R42A constructs using
Lipofectamine and serum-starved overnight. Cells were
pretreated with 20 μM LY294002 for 60 minutes and then
treated with 50 ng/ml EGF for 10 minutes. After treat-
ment cells were fixed in 4% paraformaldehyde-PBS for
15 minutes, permeabilized in 0.2% Triton X-100 in PBS
for 5 minutes, and blocked with 1% BSA in PBS for 20 mi-
nutes. First, the cells were then incubated with TRITC-
phalloidin (Sigma-Aldrich) at a final concentration of
0.1 g/ml for 20 min. After careful washing, anti-V5 anti-
body was applied in 1:1000 dilution for 30 minutes. After
washing with PBS the samples were incubated with Alexa
Fluor 488 labeled anti-mouse secondary antibody for 30 mi-
nutes. After 40 minutes of washing with PBS cover slips
were mounted onto slides in a 100 mM Tris–HCl buffer,pH 8.5, containing 10% Mowiol 4–88 (Calbiochem), 25%
glycerol, and 2.5% 1,4-diazobicyclo-[2.2.2]octane (DABCO,
Sigma-Aldrich). Tks5 membrane-localization was quanti-
fied by counting at least 100 cell/sample. Microscopy was
performed on a Zeiss LSM 710 confocal microscope.
Statistics
All quantitative results are presented as the mean and
s.d. of (at least 3) independent experiments. Statistical
differences between the groups of data were analyzed by
Student’s t-test.
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